埃博拉病毒感染的抗体疗法的持续演变。
The ongoing evolution of antibody-based treatments for Ebola virus infection.
作者信息
Mendoza Emelissa J, Racine Trina, Kobinger Gary P
机构信息
Zoonotic Diseases & Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Department of Immunology, University of Manitoba, Winnipeg, MB, Canada.
出版信息
Immunotherapy. 2017 Mar;9(5):435-450. doi: 10.2217/imt-2017-0010.
The 2014-2016 Ebola virus outbreak in West Africa was the deadliest in history, prompting the evaluation of various drug candidates, including antibody-based therapeutics for the treatment of Ebola hemorrhagic fever (EHF). Prior to 2014, only convalescent blood products from EHF survivors had been administered to newly infected individuals as a form of treatment. However, during the recent outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were either tested in a human clinical safety and efficacy trial or provided to some based on compassionate grounds. This review aims to discuss the evolution of antibody-based treatments for EHF, their clinical trial efficacy and the development of new antibody-based therapies currently advancing in preclinical testing.
2014 - 2016年西非埃博拉病毒疫情是历史上最致命的一次，促使人们对各种候选药物进行评估，包括用于治疗埃博拉出血热（EHF）的基于抗体的疗法。在2014年之前，仅将埃博拉出血热幸存者的康复期血液制品作为一种治疗形式给予新感染个体。然而，在最近这次疫情期间，诸如ZMapp、ZMAb和MB - 003等单克隆抗体鸡尾酒疗法要么在人体临床安全性和疗效试验中进行了测试，要么基于同情理由提供给了一些患者。本综述旨在讨论埃博拉出血热基于抗体治疗方法的演变、其临床试验疗效以及目前正在临床前测试中推进的新型基于抗体疗法的开发情况。
Zotero 插件